Source-grounded facts extracted from TScan Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
TScan Therapeutics, Inc. shareholders approved Approval of a Proposal to Adjourn the Annual Meeting at the 2026-05-20 meeting.
“Although Proposal No. 4 was deemed not necessary because there was a quorum present and there were sufficient proxies at the time of the Annual Meeting to approve Proposal No. 3, it was approved by the requisite vote as follows: Votes For Votes Against Abstain Broker Non-Votes 21,897,635 2,007,636 268,987 15,247,179”
TScan Therapeutics, Inc. shareholders approved Approval of an Amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of voting common stock from 300,000,000 to 600,000,000 at the 2026-05-20 meeting.
“The stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of voting common stock from 300,000,000 shares to 600,000,000 shares. The results of the stockholders’ vote with respect to such approval were as follows: Votes For Votes Against Abstain Broker Non-Votes 35,913,605 3,177,381 330,451 15,247,179”
TScan Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-20 meeting.
“The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows: Votes For Votes Against Abstain Broker Non-Votes 38,497,976 637,978 285,483 15,247,179”
TScan Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2026-05-20 meeting.
“The stockholders of the Company elected Katina Dorton, J.D., M.B.A. and R. Keith Woods as Class II directors, each to serve for a three-year term ending at the annual meeting of stockholders to be held in 2029 and until their successor has been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class II directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Katina Dorton, J.D., M.B.A. 19,665,447 4,508,811 15,247,179 R. Keith Woods 23,305,311 868,947 15,247,179”
TScan Therapeutics, Inc.: Approved amendment to Amended and Restated Certificate of Incorporation to increase authorized shares of voting common stock from 300,000,000 to 600,000,000 (effective 2026-05-20).
“the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of voting common stock from 300,000,000 to 600,000,000”
TScan Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue $1.0 million, net income $28.7 million.
“Revenue: Revenue for the first quarter of 2026 was $1.0 million, compared to $2.2 million for the first quarter of 2025. The decrease was primarily due to timing of research activities pursuant to the Company’s collaboration agreement with Amgen. R&D Expenses: Research and development (R&D) expenses for the first quarter of 2026 were $21.9 million, compared to $29.8 million for the first quarter of 2025. The decrease of $7.9 million was primarily driven by the timing in the purchase of supplies and consumables, as well as savings in connection with the Company’s previously announced strategy to prioritize the clinical development of its heme program. R&D expenses included non-cash stock compensation expense of $1.2 million and $1.7 million for the first quarter of 2026 and 2025, respectively. G&A Expenses: General and administrative (G&A) expenses for the first quarter of 2026 were $8.2 million, compared to $8.6 million for the first quarter of 2025. The decrease of $0.4 million was pr”
TScan Therapeutics, Inc. reported for the fourth quarter and fiscal year ended December 31, 2025 results: revenue $2.6 million.
“sharing preclinical proof-of-concept data for its therapeutic approach in the second half of 2026. Financial Results Revenue: Revenue for the fourth quarter of 2025 was $2.6 million, compared to $0.7 million for the fourth quarter of 2024, and $10.3 million for the full-year 2025, compared to $2.8 million for the full-year 2024. The increase in both periods”
TScan Therapeutics, Inc. announced a restructuring with charges of up to approximately $2.3 million affecting the Company (approximately 30% of the Company’s workforce, or 66 roles).
“On November 3, 2025, TScan Therapeutics, Inc. (the “Company”) initiated a prioritization strategy by which the Company will prioritize the clinical development of its heme program, pause further enrollment in its solid tumor Phase 1 trial, and focus preclinical efforts on in vivo engineering for solid tumors and target discovery in autoimmunity. Pursuant to such strategy, the Company also implemented a workforce reduction of approximately 30% of the Company’s workforce, or 66 roles. The Company expects to record a one-time charge of up to approximately $2.3 million during the three months ended December 31, 2025, for severance-related benefits and other costs.”
Garry Nicholson was appointed as Director at TScan Therapeutics, Inc..
“On June 12, 2024, the Board appointed Garry Nicholson to the Board, effective as of the Effective Date.”
Stephen Biggar changed role as Chairman of the Board at TScan Therapeutics, Inc..
“Current member of the Board, Stephen Biggar, M.D., Ph.D., assumed the role of Chairman of the Board, effective as of the Effective Date.”
Timothy Barberich resigned as Chairman of the Board and Director at TScan Therapeutics, Inc..
“On June 12, 2024 (the “Effective Date”), after the conclusion of the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of TScan Therapeutics, Inc. (the “Company”), Timothy Barberich, a member and Chairman of the Board of Directors (the “Board”) of the Company, tendered his resignation from the Board and Chairman position thereof, effective immediately.”
TScan Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.6 million.
“• Long-term duration of response data for multiplex therapy anticipated in 2025. First Quarter 2024 Financial Results Revenue: Revenue for the first quarter of 2024 was $0.6 million, compared to $6.8 million for the first quarter of 2023. The decrease was primarily due to the timing of research activities pursuant to the Company’s collaboration agreements.”
TScan Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and TD Securities (USA) LLC valued at $144.7 million (effective 2024-04-16).
“On April 16, 2024, TScan Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and TD Securities (USA) LLC, as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 2,472,581 shares (the “Firm Shares”) of its voting common stock, par value $0.0001 per share (the “Voting Common Stock”), at a price to the public of $7.1300 per share, and (b) pre-funded warrants to purchase up to 18,577,419 shares of the Company’s Voting Common Stock (the “Pre-Funded Warrants”), at a price to the public of $7.1299 per warrant with an exercise price of $0.0001 per share (the “Offering”).”
TScan Therapeutics, Inc. reported financial results for the three months and full year ended December 31, 2023.
“TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2023, and provided a business update.”
Jason A. Amello was appointed as Chief Financial Officer at TScan Therapeutics, Inc..
“On January 29, 2024, TScan Therapeutics, Inc. (the “Company”) announced the appointment of Jason A. Amello as Chief Financial Officer, which was approved by the Board of Directors of the Company on January 24, 2024, effective January 29, 2024 (the “Start Date”).”
R. Keith Woods was appointed as Class II director at TScan Therapeutics, Inc..
“On December 6, 2023, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) appointed R. Keith Woods, to the Board, effective December 6, 2023.”
TScan Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.
“On August 10, 2023, TScan Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2023.”
Leiden Dworak was appointed as Principal Accounting Officer at TScan Therapeutics, Inc..
“appointed Leiden Dworak as Principal Accounting Officer of the Company, effective July 21, 2023”
Gavin MacBeath was appointed as interim Principal Financial Officer at TScan Therapeutics, Inc..
“appointed Gavin MacBeath, Ph.D., as the interim Principal Financial Officer of the Company, effective July 21, 2023”
Brian Silver resigned as Chief Financial Officer at TScan Therapeutics, Inc..
“replacing Brian Silver, who had previously announced his resignation as Chief Financial Officer of the Company effective July 21, 2023.”
Brian Silver departed as Chief Financial Officer and Treasurer at TScan Therapeutics, Inc..
“On June 27, 2023, Mr. Brian Silver informed TScan Therapeutics, Inc. (the “Company”) of his intent to step down from his roles as Chief Financial Officer and Treasurer of the Company, effective July 21, 2023.”
TScan Therapeutics, Inc. shareholders approved Approval of Amendment of the Company's 2021 Equity Incentive Plan at the 2023-06-13 meeting.
“Proposal 3 – Approval of Amendment of the Company’s 2021 Equity Incentive Plan The stockholders of the Company approved an amendment to the Company’s 2021 Equity Incentive Plan to increase the number of shares of Common Stock that may be subject to awards. The results of the stockholders’ vote with respect to such approval were as follows: Votes For Votes Against Abstain Broker Non-Votes 6,214,939 2,915,794 96,815 3,350,413”
TScan Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-13 meeting.
“Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such ratification were as follows: Votes For Votes Against Abstain 12,320,349 257,552 60”
TScan Therapeutics, Inc. shareholders approved Election of Class II Director at the 2023-06-13 meeting.
“Proposal 1 - Election of Class II Director The stockholders of the Company elected Katina Dorton, J.D., M.B.A. as a Class II director, for a three-year term ending at the annual meeting of stockholders to be held in 2026 and until her successor has been duly elected and qualified or until her earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class II director were as follows: Name Votes For Votes Withheld Broker Non-Votes Katina Dorton, J.D., M.B.A. 7,876,146 1,351,402 3,350,413”
TScan Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and Wedbush Securities Inc., as representatives (effective 2023-05-25).
“On May 25, 2023, TScan Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC and Wedbush Securities Inc., as representatives (the “ Representatives ”) of the underwriters named therein”
Gavin MacBeath was appointed as Director at TScan Therapeutics, Inc..
“appointed Gavin MacBeath, Ph.D., as Chief Executive Officer and member the Board, effective May 24, 2023.”
Gavin MacBeath was appointed as Chief Executive Officer at TScan Therapeutics, Inc..
“appointed Gavin MacBeath, Ph.D., as Chief Executive Officer and member the Board, effective May 24, 2023.”
TScan Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.
“On May 10, 2023, TScan Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2023.”
TScan Therapeutics, Inc. entered into Agreement with Amgen Inc. valued at $30 million (effective 2023-05-08).
“On May 8, 2023, TScan Therapeutics, Inc. (“ TScan ” or the “ Company ”), entered into a Collaboration Agreement (the “ Agreement ”) with Amgen Inc. (“ Amgen ”) to identify antigens recognized by T cells in patients with Crohn’s disease utilizing the Company’s proprietary target discovery platform, TargetScan (“ TargetScan ”).”
Barbara Klencke was appointed as Director at TScan Therapeutics, Inc..
“On April 6, 2023, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) appointed Barbara Klencke, M.D., to the Board, effective April 6, 2023.”
Gavin MacBeath was appointed as acting Chief Executive Officer at TScan Therapeutics, Inc..
“On March 28, 2023, the Board appointed Gavin MacBeath, Ph.D., as acting Chief Executive Officer of the Company, effective as of March 28, 2023.”
David Southwell resigned as Chief Executive Officer and President at TScan Therapeutics, Inc..
“On March 27, 2023, Mr. David Southwell stepped down from his roles as Chief Executive Officer and President of TScan Therapeutics, Inc. (the “Company”), and as a member of the Board of Directors of the Company (the “Board”), effective immediately.”
TScan Therapeutics, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.
“On March 8, 2023, TScan Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.”
TScan Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $3.4 million.
“be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2024. Revenue for the third quarter ended September 30, 2022, was $3.4 million, compared to $2.4 million for the third quarter ended September 30, 2021 (2021 Quarter). This increase is due to research activities related to TScan’s collaboration agreement”
Dr. Debora Barton was appointed as Chief Medical Officer at TScan Therapeutics, Inc..
“On July 7, 2022, TScan Therapeutics, Inc. (the “Company”), announced the appointment of Dr. Debora Barton, M.D., to serve as the Company’s Chief Medical Officer, effective July 5, 2022.”
Gavin MacBeath changed role as Chief Scientific and Operations Officer at TScan Therapeutics, Inc..
“On June 1, 2022, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) promoted Gavin MacBeath, Ph.D. to Chief Scientific and Operations Officer.”
Christoph Westphal resigned as Director at TScan Therapeutics, Inc..
“On July 15, 2021, effective immediately after the pricing of the initial public offering (the “IPO”) of TScan Therapeutics, Inc. (the “Company”) Christoph Westphal, M.D., Ph.D., resigned from his position as a member of the Company’s board of directors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.